false
0001888886
True
0001888886
2024-08-08
2024-08-08
0001888886
gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember
2024-08-08
2024-08-08
0001888886
gpcr:OrdinarySharesParValue0.0001PerShareMember
2024-08-08
2024-08-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 8, 2024
Structure Therapeutics Inc.
(Exact name of registrant as specified in its
charter)
Cayman Islands |
|
001-41608 |
|
98-1480821 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
601 Gateway Blvd., Suite 900
South San Francisco, California |
|
94080 |
(Address of principal executive offices) |
|
(Zip Code) |
(Registrant’s telephone number, including area code): (650) 457-1978
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
|
|
| |
Name Of Each Exchange |
Title of Each Class |
|
Trading Symbol(s) |
|
On Which
Registered |
American Depositary Shares (ADSs), each representing three ordinary shares, par value $0.0001 per ordinary share |
|
GPCR |
|
Nasdaq Global Market |
|
|
|
|
|
Ordinary shares, par value $0.0001 per share* |
|
True |
|
Nasdaq Global Market* |
* Not for trading, but only in connection with the registration of
the American Depositary Shares
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On August 8, 2024, Structure Therapeutics Inc. (the
“Company”) issued a press release providing a corporate update and announcing its financial results for the second quarter
ended June 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
The information in this Current Report on Form 8-K (including
Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference
into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific
reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Structure Therapeutics Inc. |
|
|
Date: August 8, 2024 |
By: |
/s/ Raymond Stevens |
|
|
Raymond Stevens, Ph.D. |
|
|
Chief Executive Officer |
Exhibit 99.1
![](https://www.sec.gov/Archives/edgar/data/1888886/000110465924087275/tm2421118d1_ex99-1img001.jpg)
Structure Therapeutics Reports Second Quarter
2024 Financial Results and Recent Highlights
GSBR-1290 Phase 2b study in obesity on track
to initiate in the fourth quarter 2024
Oral small molecule amylin receptor agonist
development candidate expected to be selected in fourth quarter of 2024
Obesity pipeline consists of four oral small
molecule programs targeting GLP-1, GIP, amylin and APJ receptors
Strong financial position with cash balance
of $927.1 million expected to fund projected operations and key clinical milestones through at least 2027
SAN FRANCISCO – August 8, 2024 – Structure
Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics
for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter ended June 30, 2024, and highlighted
recent corporate achievements.
“The first half of 2024 was pivotal for Structure Therapeutics
with the Phase 2a obesity results demonstrating GSBR-1290 as a potential best-in-class oral small molecule, the continued advancement
of our broad oral incretin franchise, and the expansion of our clinical-stage pipeline with the initiation of our LPA1R Phase 1 trial,”
said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics. “We believe that GSBR-1290 is a differentiated oral small
molecule GLP-1 agonist with significant pharmacokinetics (PK), scalability and manufacturing advantages, and we are now focused on advancing
GSBR-1290 as rapidly as possible with the Phase 2b study expected to start before the end of the year. In the fourth quarter, we also
anticipate declaring a development candidate for our amylin program, a promising next-generation approach to obesity treatment where there
are currently no other oral small molecule candidates.”
Recent and Upcoming Milestones
Oral Small Molecule Selective GLP-1R agonist for Obesity
| · | In June 2024, the Company reported positive topline data from the Phase 2a obesity study in which GSBR-1290 demonstrated a clinically
meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks (p<0.0001) and generally favorable safety
and tolerability results following repeated, daily dosing up to 120mg. The Company also reported data from a new tablet formulation of
GSBR-1290 in a capsule to tablet PK study, which demonstrated a placebo-adjusted mean weight loss of up to 6.9% with the tablet formulation
at 12 weeks. PK data support proportional exposure between 60 and 120mg and once-daily oral dosing of GSBR-1290. These topline data were
also presented at the American Diabetes Association 84th Scientific Sessions in June. |
| · | The Company is on track to initiate a 36-week Phase 2b obesity study of GSBR-1290 in the fourth quarter of 2024. |
Oral Small Molecule GLP-1R Combination Programs: Amylin, GIPR,
Apelin Receptor (APJR)
| · | Oral Small Molecule Amylin Program: The Company is developing amylin receptor agonists for potential use either alone or in
combination with GLP-1R agonists to treat obesity and associated diseases and expects to select a development candidate in the fourth
quarter of 2024. |
| · | Oral Small Molecule GIPR Program: The Company is developing a GIPR selective agonist and GLP-1R/GIPR
combinations to treat obesity and associated diseases, and expects to select a development candidate in the first half of 2025. |
| · | Oral Small Molecule APJR Program: The Company is evaluating ANPA-0073, a Phase 2 ready biased APJR agonist for potential selective
or muscle-sparing weight loss. ANPA-0073 is also being evaluated for idiopathic pulmonary fibrosis (IPF). The Company has completed a
Phase 1 single-ascending and multiple-ascending dose study, in which ANPA-0073 was generally well-tolerated with no serious adverse events
reported. |
Oral Small Molecule LPA1R Program for IPF
| · | In June 2024, the Company initiated a Phase 1 clinical trial of LTSE-2578, an oral
small molecule antagonist that targets the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of IPF. The randomized, double-blind,
placebo-controlled first-in-human clinical trial is designed to investigate the safety, tolerability and pharmacokinetics of single and
multiple ascending doses of LTSE-2578 in approximately 64 healthy participants. |
Second Quarter 2024 Financial Highlights
Cash Position: Cash, cash equivalents and short-term investments
totaled $927.1 million on June 30, 2024. The Company expects its current cash, cash equivalents and short-term investments to fund
projected operations and key clinical milestones through at least 2027.
Research and Development (R&D) Expenses: R&D expenses
for the second quarter of 2024 were $22.1 million, as compared to $19.4 million for the same period in 2023. The increase was primarily
due to increases related to employee expenses, such as increases in personnel and consulting services, as well as the advancement of the
Company’s GLP-1R franchise and other research programs and clinical study activities.
General and Administrative (G&A) Expenses: G&A expenses
for the second quarter of 2024 were $11.3 million, as compared to $6.6 million for the same period in 2023. The increase was primarily
due to increases in employee related expenses and professional services as the Company expanded its infrastructure to drive the growth
in its operations as a publicly-traded company.
Net Loss: Net loss for the second quarter of 2024 totaled $26.0
million, with non-cash share-based compensation expense of $4.2 million, compared to $23.3 million for the second quarter of 2023 with
non-cash share-based compensation expense of $1.7 million.
About Structure Therapeutics
Structure Therapeutics is a science-driven
clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic
metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery
platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small
molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to
more patients around the world. For additional information, please visit www.structuretx.com.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without
limitation, statements concerning: the Company’s future plans and prospects; the Company’s anticipated cash runway; any expectations
regarding the safety, efficacy or tolerability of GSBR-1290 and other candidates under development; the ability of GSBR-1290 to treat
T2DM, obesity or related indications; the planned initiation and study design of the Company’s Phase 2 and Phase 2b studies of GSBR-1290
in patients with T2DM and obesity and the timing thereof; the selection of a development candidate for the Company’s amylin receptor
agonist program; the timing and design of the Company’s amylin receptor agonist program and its potential as a promising approach
to obesity treatment; the timing and design of the Company’s GIPR and GLP-1R/GIPR programs; the potential for GSBR-1290 to be a
best-in-class oral small molecule and its potential scaling and manufacturing advantages; the potential applications of ANPA-0073; and
the planned timing of the Company’s data results and continued development of LTSE-2578. In addition, when or if used in this press
release, the words and phrases “expect,” “on track,” “plan,” “potential,” “promising,”
“to be,” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements.
Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations
reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be
correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially
from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include,
without limitation, risks and uncertainties related to the fact that topline
results that the Company reports is based on a preliminary analysis of key efficacy and safety data, and such data may change following
a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results
of a clinical trial, the preliminary nature of the results due to length of the study and sample size and results from earlier clinical
trials not necessarily being predictive of future results, including the results using the least square means and mixed model for repeated
measures which uses all available data, including data from patients who did not follow-up at 12 weeks, and estimates how patients with
missing data would have responded based on patients who continued the study and had similar baseline characteristics (implicit imputation),
potential delays in the IND submission or commencement, enrollment and completion of the Company’s planned Phase 2 trials, including
that the Company will need to receive allowance from the FDA to proceed before initiating the planned Phase 2b trial, the Company’s
ability to advance GSBR-1290, LTSE-2578, ANPA-0073 and its other therapeutic candidates, obtain regulatory approval of and ultimately
commercialize the Company’s therapeutic candidates, competitive products or approaches limiting the commercial value of the Company’s
product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities
and achieve development goals, the impact of any global pandemics, inflation, supply chain issues, rising interest rates and future bank
failures on the Company’s business, its ability to protect its intellectual property and other risks and uncertainties described
in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K
for the year ended December 31, 2023, as filed with the SEC on March 8, 2024, the Quarterly Report on Form 10-Q filed with
the SEC on May 9, 2024, and future reports the Company may file with the SEC from time to time. All forward-looking statements contained
in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates
as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist
after the date on which they were made, except as required by law.
STRUCTURE THERAPEUTICS INC.
Condensed Consolidated Statements of Operations
(unaudited)
(In thousands)
| |
THREE MONTHS ENDED | | |
SIX MONTHS ENDED | |
| |
JUNE 30, | | |
JUNE 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
$ | 22,050 | | |
$ | 19,411 | | |
$ | 42,729 | | |
$ | 32,546 | |
General and administrative | |
| 11,266 | | |
| 6,576 | | |
| 22,602 | | |
| 13,090 | |
Total operating expenses | |
| 33,316 | | |
| 25,987 | | |
| 65,331 | | |
| 45,636 | |
Loss from operations | |
| (33,316 | ) | |
| (25,987 | ) | |
| (65,331 | ) | |
| (45,636 | ) |
Interest and other income, net | |
| 7,335 | | |
| 2,825 | | |
| 13,343 | | |
| 4,524 | |
Loss before provision for income taxes | |
| (25,981 | ) | |
| (23,162 | ) | |
| (51,988 | ) | |
| (41,112 | ) |
Provision for income taxes | |
| 53 | | |
| 118 | | |
| 82 | | |
| 143 | |
Net loss | |
$ | (26,034 | ) | |
$ | (23,280 | ) | |
$ | (52,070 | ) | |
$ | (41,255 | ) |
STRUCTURE THERAPEUTICS INC.
Condensed Consolidated Balance Sheet Data
(unaudited)
(In thousands)
| |
JUNE 30, | | |
DECEMBER 31, | |
| |
2024 | | |
2023 | |
Assets | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash, cash equivalents and short-term investments | |
$ | 927,119 | | |
$ | 467,323 | |
Prepaid expenses and other current assets | |
| 10,502 | | |
| 6,285 | |
Total current assets | |
| 937,621 | | |
| 473,608 | |
Property and equipment, net | |
| 3,315 | | |
| 3,228 | |
Operating right-of-use assets | |
| 4,267 | | |
| 5,136 | |
Other non-current assets | |
| 1,826 | | |
| 45 | |
Total assets | |
$ | 947,029 | | |
$ | 482,017 | |
Liabilities and shareholders’ equity | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 2,209 | | |
$ | 4,742 | |
Accrued expenses and other current liabilities | |
| 18,821 | | |
| 18,558 | |
Operating lease liabilities, current portion | |
| 1,629 | | |
| 1,440 | |
Total current liabilities | |
| 22,659 | | |
| 24,740 | |
Operating lease liabilities, net of current portion | |
| 3,045 | | |
| 4,013 | |
Other non-current liabilities | |
| 293 | | |
| 298 | |
Total liabilities | |
| 25,997 | | |
| 29,051 | |
Total shareholders’ equity | |
| 921,032 | | |
| 452,966 | |
Total liabilities and shareholders’ equity | |
$ | 947,029 | | |
$ | 482,017 | |
Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
v3.24.2.u1
Cover
|
Aug. 08, 2024 |
Document Information [Line Items] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 08, 2024
|
Entity File Number |
001-41608
|
Entity Registrant Name |
Structure Therapeutics Inc.
|
Entity Central Index Key |
0001888886
|
Entity Tax Identification Number |
98-1480821
|
Entity Incorporation, State or Country Code |
E9
|
Entity Address, Address Line One |
601 Gateway Blvd.
|
Entity Address, Address Line Two |
Suite 900
|
Entity Address, City or Town |
South San Francisco
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94080
|
City Area Code |
650
|
Local Phone Number |
457-1978
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
American Depositary Shares Adss Each Representing Three Ordinary Shares Par Value 0. 0001 Per Ordinary Share [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
American Depositary Shares (ADSs), each representing three ordinary shares, par value $0.0001 per ordinary share
|
Trading Symbol |
GPCR
|
Security Exchange Name |
NASDAQ
|
Ordinary Shares Par Value 0. 0001 Per Share [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Ordinary shares, par value $0.0001 per share*
|
No Trading Symbol Flag |
true
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a security having no trading symbol.
+ References
+ Details
Name: |
dei_NoTradingSymbolFlag |
Namespace Prefix: |
dei_ |
Data Type: |
dei:trueItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=gpcr_AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=gpcr_OrdinarySharesParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Structure Therapeutics (NASDAQ:GPCR)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Structure Therapeutics (NASDAQ:GPCR)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024